Table 3. . Select ongoing clinical trials of rucaparib in different solid tumors.
| Study | Drug | Setting | Phase |
|---|---|---|---|
| TRITON 2 NCT 02952534 |
Rucaparib | Metastatic castration-resistant prostate cancer and HRD | II |
| TRITON 3 NCT 02975934 |
Rucaparib | Metastatic castration-resistant prostate cancer and HRD | III |
| NCT03442556 | Docetaxel, carboplatin and rucaparib | Metastatic castration-resistant prostate cancer and HRD | II |
| CheckMate 9KD (NCT0333879) |
Nivolumab and rucaparib | Metastatic castration-resistant prostate cancer | II |
| NCT03413995 | Rucaparib | Metastatic castration-resistant sensitive cancer and HRD | II |
| ATLAS NCT03397394 |
Rucaparib | Metastatic urothelial carcinoma | II |
| NCT 02042378 | Rucaparib | Pancreatic cancer and a BRCA mutation | II |
| RUBY 2 NCT 02505048 |
Rucaparib | Metastatic breast cancer with a BRCAness genomic signature | II |
| NCT01074970 | Rucaparib | Triple negative breast cancer with BRCA1/2 mutations | II |
| NCT 01482715 | Rucaparib | Advanced solid tumors with BRCA mutation | I |
| NCT 03101280 | Rucaparib | Advanced gynecologic cancers and triple negative breast cancer | Ib |
| NCT 03101280 | Rucaparib and atezolizumab | Advanced gynecologic cancers and triple negative breast cancer | II |
| NCT 03476798 | Bevacizumab and rucaparib | Recurrent carcinoma of the cervix or endometrium | II |
| NCT 03337087 | Irinotecan, fluorouracil and rucaparib | Metastatic pancreatic, colorectal, gastroesophageal, or biliary cancer | I/II |
AE: Adverse event; DLT: Dose limiting toxicity; HRD: Homologous recombination deficiency; ORR: Objective response rate; PSA: Prostate specific antigen; PK: Pharmacokinetic.